KOREA ARLICO PHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,890 KRW | 0.00% |
|
-2.00% | -14.21% |
| 2023 | Korea Arlico Pharm Co.,Ltd. announced that it has received KRW 10 billion in funding | CI |
| 2023 | Korea Arlico Pharm Co.,Ltd. announced that it expects to receive KRW 10 billion in funding | CI |
| Sales 2022 | 168B 121M 165M | Sales 2023 | 187B 135M 184M | Capitalization | 87.36B 62.81M 85.79M |
|---|---|---|---|---|---|
| Net income 2022 | 8.03B 5.78M 7.89M | Net income 2023 | 3.06B 2.2M 3.01M | EV / Sales 2022 | 0.59 x |
| Net cash position 2022 | 1.11B 796K 1.09M | Net Debt 2023 | 15.5B 11.14M 15.22M | EV / Sales 2023 | 0.55 x |
| P/E ratio 2022 |
12.3
x | P/E ratio 2023 |
54.8
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 57.82% |
More Fundamentals
* Assessed data
More news
| 1 week | -2.00% | ||
| Current month | +0.10% | ||
| 1 month | -3.17% | ||
| 3 months | -8.94% | ||
| 6 months | -16.27% | ||
| Current year | -14.21% |
1 week
4 840.00
5 000.00
1 month
4 830.005 420.00
Current year
4 830.005 900.00
1 year
4 830.007 480.00
3 years
4 830.0010 800.00
5 years
4 012.7012 000.00
10 years
4 012.7021 174.60
| Managers | Title | Age | Since |
|---|---|---|---|
Hang-Gu Lee
CEO | Chief Executive Officer | 63 | - |
Chan-Sub Kim
BRD | Director/Board Member | 58 | 19-03-13 |
Yong-Hwa Lee
AUD | Comptroller/Controller/Auditor | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hang-Gu Lee
CEO | Chief Executive Officer | 63 | - |
Chan-Sub Kim
BRD | Director/Board Member | 58 | 19-03-13 |
Moon-Sung Lee
BRD | Director/Board Member | 57 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-25 | 4,860 | -0.61% | 9,492 |
| 24-06-24 | 4,890 | 0.00% | 12,766 |
| 24-06-21 | 4,890 | -0.81% | 16,164 |
| 24-06-20 | 4,930 | -0.70% | 5,712 |
| 24-06-19 | 4,965 | -0.30% | 24,462 |
End-of-day quote Korea S.E., June 23, 2024
More quotes
KOREA ARLICO PHARM CO.,LTD. is a Korea-based company that mainly engaged in the manufacturing and sale of pharmaceuticals. The Company manufactures and sells circulation system drugs, digestion drugs, anti-inflammatory analgesic, other prescription drug for treating hypertension, hyperlipidemia, peptic ulcer, indigestion, osteoarthritis, pain, and dementia, among others. The Company distributes its products within the domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.21% | 53.54M | |
| +20.22% | 43.29B | |
| +27.64% | 22.38B | |
| +20.51% | 15.51B | |
| +19.31% | 14.52B | |
| +56.05% | 12.93B | |
| -0.05% | 6.79B | |
| -11.39% | 6.56B | |
| +17.73% | 5.87B | |
| -8.87% | 5.73B |
- Stock Market
- Equities
- A260660 Stock
